Patents Issued in February 9, 2021
  • Patent number: 10912763
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: February 9, 2021
    Assignee: Grünenthal GmbH
    Inventors: Nadja Gruening, Marc Schiller, Ashish Hemani, Chris Kirby, Ingo Friedrich, John Bothmer, Andreas Scholz
  • Patent number: 10912764
    Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: February 9, 2021
    Assignee: The Regents of the University of California
    Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
  • Patent number: 10912765
    Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: February 9, 2021
    Assignee: VOOM, LLC
    Inventor: Mark Silverberg
  • Patent number: 10912766
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
  • Patent number: 10912767
    Abstract: The present invention includes compounds of the class anthracycline that have been modified to include photo-activated prodrug anthracycline compounds that are useful in the treatment of cancer. One example composition of the invention may include photodoxazolidine which may be synthesized in two steps from 4,5-dimethoxy-2-nitrobenzyl alcohol and doxazolidine. In this embodiment commercial 4,5-dimethoxyl-2-nitrobenzyl alcohol reacts with p-nitrophenylchloroformate to give the p-nitrophenyl carbonate of the benzyl alcohol derivative. The p-nitrophenyl carbonate is then reacted with doxazolidine to give the exemplary photodoxazolidine composition.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 9, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Tad H. Koch, Benjamin L. Barthel, Hang Hubert Yin, Ryo Tamura, Alla Balabanova
  • Patent number: 10912768
    Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 9, 2021
    Assignee: Romark Laboratories L.C.
    Inventors: Jean-Francois Rossignol, J. Edward Semple
  • Patent number: 10912769
    Abstract: Provided in the present invention are a 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative having the structure shown below in formula (I) and a pharmaceutical composition and use thereof. The 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative provided in the present invention has good gastric acid secretion inhibitory activities and excellent pharmacodynamic properties, while having relatively low toxicity.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 9, 2021
    Assignees: Jiangsu Jibeier Pharmaceutical Co. Ltd., Zhenjiang San An Pharmaceutical Co. Ltd.
    Inventors: Zhongyi Geng, Xinghai Chen
  • Patent number: 10912770
    Abstract: The invention relates to the use of adenosine monophosphate deaminase 2 (AMPD2) inhibitors alone or in combination with various agents to treat a wide variety of diseases including, but not limited to, sugar craving, salt craving, umami craving, and addictions including drug, tobacco, nicotine and alcohol addictions. Embodiments of the invention may also relate to stimulation of AMPD2 activity to treat anorexia nervosa or stimulate food intake in a subject.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 9, 2021
    Assignee: Regents of the University of Colorado, A Body Corporate
    Inventors: Richard J Johnson, Ana Andres Hernando, Miguel A Lanaspa Garcia
  • Patent number: 10912771
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Grant
    Filed: October 17, 2020
    Date of Patent: February 9, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Patent number: 10912772
    Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: February 9, 2021
    Assignee: Camurus AB
    Inventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
  • Patent number: 10912773
    Abstract: The present invention provides combination treatments comprising compounds of Formula (I): that are PDE1 enzyme inhibitors, and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: February 9, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
  • Patent number: 10912774
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 9, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
  • Patent number: 10912775
    Abstract: Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: February 9, 2021
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Songliang Wu, Zhi Luo, Yuan Chen, Yuhe Wang, Dakun Qin, Xiaolin Li, Zheng Wang, Weidong Li, Haiying He
  • Patent number: 10912776
    Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: February 9, 2021
    Assignee: CORVUS PHARMACEUTICALS, INC.
    Inventors: Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian McCaffery, Andrew Hotson
  • Patent number: 10912777
    Abstract: A pharmaceutical composition comprising (i) a therapeutically effective amount of an inhibitor of the oncogene SLC29A2; and (ii) a pharmaceutically acceptable carrier, for use in suppressing proliferation, occurrence, and metastasis of cancer cells overexpressing the oncogene SLC29A2 in a cancer patient, and/or prolonging cancer patient survival. The inhibitor of the oncogene SLC29A2 may be at least one selected from the group consisting of dipyridamole, dilazep, draflzine, nitorbenzylthioinosine, and the derivatives thereof. The composition for use may further comprise sorafenib for the same use.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: February 9, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Yuh-Shan Jou, Roger Shen
  • Patent number: 10912778
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 9, 2021
    Assignee: RESPIRA THERAPEUTICS, INC.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Patent number: 10912779
    Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: February 9, 2021
    Assignee: Asana BioSciences, LLC
    Inventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
  • Patent number: 10912780
    Abstract: The present disclosure relates to compounds of Formula I, or their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 9, 2021
    Assignee: Bugworks Research, Inc.
    Inventors: Shahul Hameed Peer Mohamed, Nagakumar Bharatham, Nainesh Katagihallimath, Sreevalli Sharma, Radha Nandishaiah, Vasanthi Ramachandran, Balasubramanian Venkataraman
  • Patent number: 10912781
    Abstract: A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 9, 2021
    Assignee: BIAL-Portela & C.A., S.A.
    Inventors: Teöfilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
  • Patent number: 10912782
    Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: February 9, 2021
    Assignee: Antares Pharma, Inc.
    Inventors: Paul K. Wotton, Hermanus L. Jooste, Kaushik J. Dave, Jonathan Jaffe
  • Patent number: 10912783
    Abstract: Compositions and methods for the solubilization of steroid hormones are disclosed.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: February 9, 2021
    Assignee: THERAPEUTICSMD, INC.
    Inventors: Thorsteinn Thorsteinsson, Frederick D. Sancilio, Brian A. Bernick, Julia M. Amadio
  • Patent number: 10912784
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 9, 2021
    Assignee: SUZHOU NEUPHARMA CO., LTD.
    Inventor: Xiangping Qian
  • Patent number: 10912785
    Abstract: A medical device for the treatment of papilloma virus (HPV) skin infections is the object of this invention, in particular for the treatment of warts and related pathologies. In particular, this invention relates to acetylsalicylic acid for use in the topical treatment, of HPV skin infections in particular benign infections and more in particular warts. Acetylsalicylic acid may be administered by plaster or patch, both in a solid state, such as a tablet, powder or granulate, and by a hydrophilic or hydrophobic gel.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: February 9, 2021
    Assignee: Poli MD S.R.L.
    Inventor: Elena Poli
  • Patent number: 10912786
    Abstract: Described herein are silyl monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. Such multimer forming associations of monomers may be promoted by the proximal binding of the monomers to their target biomolecule(s). In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 9, 2021
    Assignees: Cornell University, Purdue Research Foundation
    Inventors: Francis Barany, Maneesh Pingle, Donald E. Bergstrom, Sarah F. Giardina, Lee Daniel Arnold
  • Patent number: 10912787
    Abstract: Methods of preventing or delaying the weakening of as well as improving the strengthening of muscles includes the step of providing an effective amount or dose of N-acetylglucosamine (GlcNAc), related saccharides, or combinations thereof both to improve myogenesis.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 9, 2021
    Assignee: PurePharm, Inc.
    Inventors: Sachiko Sato, Masahiko Sato, Ann Rancourt
  • Patent number: 10912788
    Abstract: Provided herein are methods of treating constipation in subjects in need thereof. The method includes administering a therapeutically effective dosage of N-acetylglucosamine. Subjects who may benefit from treatment include those having synucleinopathies, including Parkinson's Disease.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: February 9, 2021
    Assignee: PurePharm, Inc.
    Inventors: Willem Wassenaar, Alfonso Fasano
  • Patent number: 10912790
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 9, 2021
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Patent number: 10912791
    Abstract: Provided herein are nanoparticles comprising antisense-encoded erythropoietin receptor (RopE) alone or in combination with erythropoietin receptor (EpoR). Also provided herein are methods of treating or preventing lungs disorders comprising administering RopE alone or in combination with EpoR.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: February 9, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Connie Hsia, Orson W. Moe, Kytai Nguyen
  • Patent number: 10912792
    Abstract: Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof. A RAAS pathway related disease, disorder and/or condition in an individual such as hypertension can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to AGT.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 9, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Mark J. Graham, Punit P. Seth, Susan M. Freier
  • Patent number: 10912793
    Abstract: The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: February 9, 2021
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Richard Zager, Ali C M Johnson
  • Patent number: 10912794
    Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 9, 2021
    Assignee: KEMIN INDUSTRIES, INC.
    Inventors: Geoffrey Paul Horst, Robert Bernard Levine
  • Patent number: 10912795
    Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: February 9, 2021
    Assignee: Exela Pharma Sciences, LLC
    Inventors: John Maloney, Aruna Koganti, Phanesh Koneru
  • Patent number: 10912796
    Abstract: A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 9, 2021
    Assignee: Albion Laboratories, Inc.
    Inventor: Jonathan David Bortz
  • Patent number: 10912797
    Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: February 9, 2021
    Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Patent number: 10912798
    Abstract: A method is provided, inter alia, for treating a subject suffering from an infectious or neoplastic disease with immunotherapy. The method includes determining the critical concentration of immune cells required to treat or eradicate an infectious or neoplastic disease in the subject using an in vitro assay of the present invention; and administering to the subject the critical concentration of immune cells determined in the assay.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 9, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
  • Patent number: 10912799
    Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: February 9, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
  • Patent number: 10912800
    Abstract: The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 9, 2021
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Ronald M. Evans, Eiji Yoshihara, Michael R. Downes, Ruth T. Yu, Annette R. Atkins
  • Patent number: 10912801
    Abstract: The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: February 9, 2021
    Assignee: DUKE UNIVERSITY
    Inventors: Joanne Kurtzberg, Geraldine Dawson, Jesse Troy, Jessica Sun
  • Patent number: 10912802
    Abstract: The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs. lactis (B. lactis), Bifidobacterium longum and Lactobacillus rhamnosus, in particular the strains B. lactis CECT 8145, B. longum ES1 CECT 7347 and/or L. rhamnosus CECT 8361, in the treatment and/or prevention of psoriasis outbreaks or psoriasis.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: February 9, 2021
    Assignees: Bionou Research, S.L., KOROTT, S.L., BIOPOLIS, S.L.
    Inventors: Vicente Manuel Navarro López, Ana Adela Ramírez Boscá, José Manuel Pérez Orquín, Daniel Ramón Vidal, Salvador Genovés Martínez, María Empar Chenoll Cuadros, Francisco Manuel Codoñer Cortés
  • Patent number: 10912803
    Abstract: A composition containing the probiotic strain Lactobacillus johnsonii CNCM 1-1225 in combination with a polyphenol for use in the treatment or prevention of a cognitive and/or neurodegenerative disorder, in particular Alzheimer's disease. The polyphenol can be one or more of rosmarinic acid, chicoric acid, or caftaric acid, and can be provided in the form of a plant extract.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 9, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Rachid Bel-Rhlid, Jane Durga, Tina Kunz, Jeroen Antonius Johannes Schmitt
  • Patent number: 10912804
    Abstract: The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: February 9, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Barry John Byrne, Darin J. Falk, Christina Pacak, Lara Robert DeRuisseau, Cathryn Mah, David D. Fuller
  • Patent number: 10912805
    Abstract: The present invention relates to an extract of algae from the order of ulvales, in particular an extract of green algae of the Ulva type, for its use for modulating the immune response in a human being or an animal, in particular for stimulating the immune response with view to infections. It also relates to the non-therapeutic use of an extract of green algae of the Ulva type for modulating the immune response.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: February 9, 2021
    Assignee: AMADEITE
    Inventors: Hervé Demais, Pi Nyvall Collèn, Matthieu Le Goff, Isabelle Le Cheviller
  • Patent number: 10912806
    Abstract: There is a composition comprising an essential oil, namely a cannabis essential oil that is compatible with a prophylactic such as a condom. The cannabis essential oil comprises an active ingredient, tetrahydrocannabinol, which heightens the sensation and causes a euphoric feeling during intimate relations. There is a kit allowing for easy access to both the essential oil and condom that comprises two chambers, one chamber for storing the essential oil and the second chamber for storing the condom. The two chambers are easily separable by tearing along the perforated portion. There is a packet comprising two separable chambers for storing the composition comprising the essential oil and a prophylactic.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: February 9, 2021
    Inventor: Michael McGowan
  • Patent number: 10912807
    Abstract: Method for preparing full spectrum cannabis elixir is disclosed. The method comprises steps of breaking cannabis buds into small pieces to form an organic mixture and placing this organic mixture in an oven safe container. The container may be placed in an oven for decarboxylating the organic mixture. The decarboxylated mixture may be mixed and shaken with cold high proof grain alcohol to form an intermediate. Alternatively, the decarboxylated mixture and alcohol is mixed in magical butter or mighty fast herbal infuser to form an intermediate. This intermediate may be filtered using a press or coffee filter. Alcohol content may be removed from this filtered mixture using solvent extractor and water bath. This extract is mixed with organic cold pressed extra virgin coconut oil and lecithin liquid. Lastly, organic cold pressed unrefined hemp seed oil is added and stirred thoroughly to form a full spectrum cannabis extract (Keira's Elixir).
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: February 9, 2021
    Inventor: Sheldon I.B. Straker
  • Patent number: 10912808
    Abstract: An apparatus for applying a portion of a plant product to the epidermis of a human, the apparatus adapted to be removably fastened with a belt or strap to a human body, comprising: the belt or strap; at least one pocket or container adapted to removably receive the portion of the plant product, the at least one pocket or container comprising: a contact portion that contacts the human body, when the apparatus is removably fastened to the human body, an opposing portion, opposing the contact portion, the opposing portion adapted to allow the portion of the plant product to be removably inserted into the at least one pocket or container, the contact portion having a plurality of holes, the plurality of holes allowing the portion of the plant product to contact the epidermis, when the plant product is removably inserted into the at least one pocket or container.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: February 9, 2021
    Inventor: Joseph Lichtenstein
  • Patent number: 10912809
    Abstract: The present invention relates to an enhancer for catechin uptake enhancer in enterocytes, wherein, by mixing a green tea extract containing catechin as an active ingredient, a Dendropanax morbifera extract, and an onion extract at a proper ratio, the stability in the digestive organ can be improved and, eventually, the catechin uptake in enterocytes can be enhanced.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 9, 2021
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Su Kyung Kim, Jin Oh Chung, Wan Gi Kim, Jeong Kee Kim, Song Seok Shin, Soon Mi Shim, Da Yeon Lee, Sang Ryun Yim, Eun Hye Choi
  • Patent number: 10912810
    Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: February 9, 2021
    Assignees: Phibro Animal Health Corporation, Desert King International LLC
    Inventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
  • Patent number: 10912811
    Abstract: The present invention relates to a composition for improving peripheral circulation and lymph drainage. The composition includes at least one extract of a fatty plant, at least one extract of a plant having astringent properties, and at least one extract of a plant with one or more effects including anti-inflammatory, formation of new, healthy collagen fibrilles, antiseptic properties, antioxidant, neutralizing free radicals, antiedematous, vitaminazing, and stimulating wound healing. The composition may be used to treat at least one of varicose veins, swollen legs, painful legs, stasis dermatitis, swollen arms, indurated arms, hematomas, ecchymosis, periorbital dark circles, periorbital swelling, and hemorrhoids.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: February 9, 2021
    Inventors: Felician Stancioiu, Daniela Catanas
  • Patent number: 10912812
    Abstract: Method of preparing a botanical extract that includes contacting a raw botanical with a solvent having a dielectric constant ranging from about 2.3 to about 25 and allowing the mixture to reside for a sufficient time to obtain a crude extract; filtering out remaining raw botanical and evaporating the solvent from the crude extract under reduced pressure to obtain a dried crude extract; washing the dried crude extract with a polar solvent having a dielectric constant of no less than 30, heating the resulting mixture, and allowing to cool to ambient; collecting a filtrate from the above cooled mixture; washing the collected filtrate with a non-polar solvent having a dielectric constant of no more than 2.0; and filtering and drying the mixture to obtain the botanical extract.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: February 9, 2021
    Assignee: Signum Biosciences, Inc.
    Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
  • Patent number: 10912813
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: February 9, 2021
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy